Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48


Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases.

Memon AB, Javed A, Caon C, Srivastawa S, Bao F, Bernitsas E, Chorostecki J, Tselis A, Seraji-Bozorgzad N, Khan O.

PLoS One. 2018 Jan 8;13(1):e0190425. doi: 10.1371/journal.pone.0190425. eCollection 2018.


Central Nervous System Infections Associated with Immunosuppressive Therapy for Rheumatic Disease.

Bradshaw MJ, Cho TA, Chow FC.

Rheum Dis Clin North Am. 2017 Nov;43(4):607-619. doi: 10.1016/j.rdc.2017.06.009. Epub 2017 Aug 23. Review.


Pathophysiology of thrombotic thrombocytopenic purpura.

Sadler JE.

Blood. 2017 Sep 7;130(10):1181-1188. doi: 10.1182/blood-2017-04-636431. Epub 2017 Aug 2. Review.


Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis.

Gelfand JM, Cree BAC, Hauser SL.

Neurotherapeutics. 2017 Oct;14(4):835-841. doi: 10.1007/s13311-017-0557-4. Review.


A meta-analysis to determine the efficacy and tolerability of anti-B-cell monoclonal antibodies in multiple sclerosis.

Xie Q, Li X, Sun J, Yuan B, Li Y, Wang L, Wang M.

Exp Ther Med. 2017 Jun;13(6):3061-3066. doi: 10.3892/etm.2017.4298. Epub 2017 Apr 4.


Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.

Bittner S, Ruck T, Wiendl H, Grauer OM, Meuth SG.

Ther Adv Neurol Disord. 2017 Jan;10(1):51-66. doi: 10.1177/1756285616666741. Epub 2016 Sep 2. Review.


Progressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency.

Misbah SA.

Clin Exp Immunol. 2017 Jun;188(3):342-352. doi: 10.1111/cei.12948. Epub 2017 Mar 27. Review.


What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?

Humphreys J, Hyrich K, Symmons D.

Arthritis Res Ther. 2016 Dec 1;18(1):282. Review.


Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.

Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K, Islam-Jakobsson P, Malmeström C, Axelsson M, Vågberg M, Sundström P, Lycke J, Piehl F, Svenningsson A.

Neurology. 2016 Nov 15;87(20):2074-2081. Epub 2016 Oct 19.


Rituximab for Rheumatoid Arthritis.

Cohen MD, Keystone E.

Rheumatol Ther. 2015 Dec;2(2):99-111. Epub 2015 Aug 19. Review.


Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.

Maas RP, Muller-Hansma AH, Esselink RA, Murk JL, Warnke C, Killestein J, Wattjes MP.

J Neurol. 2016 Oct;263(10):2004-21. doi: 10.1007/s00415-016-8217-x. Epub 2016 Jul 11.


Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.

Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, Yao W, Li J, Streicher K, McKeever K, White B, Katz E, Drappa J, Sweeny S, Herbst R.

Arthritis Res Ther. 2016 Jun 7;18(1):131. doi: 10.1186/s13075-016-1021-2.


An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica.

Collongues N, de Seze J.

Ther Adv Neurol Disord. 2016 May;9(3):180-8. doi: 10.1177/1756285616632653. Epub 2016 Mar 23. Review.


Obinutuzumab for the treatment of indolent lymphoma.

Edelmann J, Gribben JG.

Future Oncol. 2016 Aug;12(15):1769-81. doi: 10.2217/fon-2016-0084. Epub 2016 Apr 27. Review.


PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents.

Kanth KM, Solorzano GE, Goldman MD.

Neurol Clin Pract. 2016 Apr;6(2):e17-e19. No abstract available.


Neurologic Emergencies in the Patients With Cancer.

Lin AL, Avila EK.

J Intensive Care Med. 2017 Feb;32(2):99-115. doi: 10.1177/0885066615619582. Epub 2016 Jul 9. Review.


Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers.

Lo Re M, Capobianco M, Ragonese P, Realmuto S, Malucchi S, Berchialla P, Salemi G, Bertolotto A.

Neurol Ther. 2015 Dec;4(2):147-57. doi: 10.1007/s40120-015-0038-9. Epub 2015 Dec 8.


Progressive multifocal leukoencephalopathy: current treatment options and future perspectives.

Pavlovic D, Patera AC, Nyberg F, Gerber M, Liu M; Progressive Multifocal Leukeoncephalopathy Consortium.

Ther Adv Neurol Disord. 2015 Nov;8(6):255-73. doi: 10.1177/1756285615602832. Review.


CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection.

Wollebo HS, Bellizzi A, Kaminski R, Hu W, White MK, Khalili K.

PLoS One. 2015 Sep 11;10(9):e0136046. doi: 10.1371/journal.pone.0136046. eCollection 2015.


Immune interventions to preserve β cell function in type 1 diabetes.

Ehlers MR.

J Investig Med. 2016 Jan;64(1):7-13. Review.

Supplemental Content

Support Center